<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181623</url>
  </required_header>
  <id_info>
    <org_study_id>2003P001209-1</org_study_id>
    <nct_id>NCT00181623</nct_id>
  </id_info>
  <brief_title>Recombinant Human Prolactin for Lactation Induction</brief_title>
  <official_title>Recombinant Human Prolactin for Lactation Induction in Prolactin Deficient Mothers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and determine the effects of the hormone&#xD;
      prolactin on lactation (breast milk production).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of recombinant human prolactin (r-hPRL) for treatment of primary lactation&#xD;
      insufficiency in women with prolactin deficiency, either congenital or acquired, will be&#xD;
      examined. Subjects will participate in an open-label study of r-hPRL administration for&#xD;
      prolactin deficiency. On study day 1, subjects will be seen between 8 and 10 am. A baseline&#xD;
      prolactin level will be obtained. Subjects will subsequently be taught to use a breast pump&#xD;
      by a designated lactation consultant and will pump for 10 minutes at each breast,&#xD;
      simultaneously or sequentially. Any milk production will be recorded, along with milk volume&#xD;
      throughout the study. Prolactin levels will be obtained every 10 minutes for 60 minutes after&#xD;
      pumping begins, then every 30 minutes for a total of 3 hours. At 3 hours, r-hPRL 60 mg/kg&#xD;
      will be administered SC. Blood will be drawn every 2 hours for 8 hours to obtain a peak&#xD;
      prolactin level. Vital signs will be monitored every 15 minutes for the first hour, then&#xD;
      every 2 hours for a total of 8 hours. Subjects will again pump both breasts 0, 3 and 6 hours&#xD;
      after the r-hPRL injection, to maintain an every 3 hour schedule. Any milk production will be&#xD;
      recorded. Subjects will administer their second dose of SC r-hPRL 12 hours after the first&#xD;
      dose.&#xD;
&#xD;
      Subjects will continue every 12 hour SC r-hPRL administration for the next 28 days. They will&#xD;
      also pump every 3 hours, with the exception of a 5 hour break for sleep at one time during&#xD;
      the 24 hours, as long as the total number of pumping episodes equals 8. Subjects will record&#xD;
      any milk production and will call as soon as any milk is expressed. When the first milk is&#xD;
      produced, the infant will not be allowed to suckle at the breast until the milk is tested and&#xD;
      readministered to the infant in a controlled setting to avoid any potential risks or r-hPRL&#xD;
      exposure to the infant in the interim. After each pumping episode, if no milk is produced&#xD;
      mothers will be encouraged to let their infants feed at the breast using a Lact-Aid device.&#xD;
&#xD;
      Subjects will be seen in the GCRC, weekly for 28 days. At each visit, subjects will have a&#xD;
      breast exam for galactorrhea and a baseline prolactin level, then subjects will administer&#xD;
      their own SC r-hPRL injection and pump at 0, 3 and 6 hours after r-hPRL administration, as&#xD;
      described above. Any milk production will be recorded. In addition, at the end of week 1 and&#xD;
      on the final day, r-hPRL will be administered, blood will be drawn every 2 hours for&#xD;
      prolactin levels as on the first day of the injection, for a total of 8 hours, and subjects&#xD;
      will pump and milk volume will be recorded at 0, 3 and 6 hours after r-hPRL administration.&#xD;
&#xD;
      When at least 0.25 cc of milk is produced by pumping, it will be sent for a prolactin level&#xD;
      measurement to determine whether levels are elevated compared to levels in the control milk.&#xD;
      If the prolactin level is not elevated, milk will be readministered to the infant. When&#xD;
      breast milk is first given to the infants, they will be monitored in the GCRC under the&#xD;
      supervision of a neonatologist, with vital signs, including temperature, measured every hour&#xD;
      after feeding for 4 hours. The mother will also record stool and gastric output and any&#xD;
      changes noted in the quality or quantity of output for the following 24 hours. If any&#xD;
      significant and adverse changes in vital signs or gastric output are observed, any additional&#xD;
      stored breast milk will be discarded and the study stopped. After the prolactin level in milk&#xD;
      has been documented in the normal range and milk readministered to the infant under&#xD;
      supervision in the GCRC, mothers will continue to pump immediately after the am r-hPRL dose,&#xD;
      but at all other times will be encouraged to breastfeed.&#xD;
&#xD;
      When at least 1 cc of milk is available, milk composition will also be analyzed for fat,&#xD;
      protein, glucose, lactose and IgA levels (see Procedure for Analyzing Collected Milk, above).&#xD;
      Studies in mothers of premature infants will be performed before starting this protocol. If&#xD;
      the level of any of these components is 50% below the lower limit of normal, breast milk will&#xD;
      be supplemented with formula at a ratio determined by the neonatologist to ensure that all&#xD;
      nutrients are received.&#xD;
&#xD;
      After completing 28 days of every 12 hour r-hPRL administration, breast milk production will&#xD;
      continue to be monitored for a 14 day control period. Subjects will be seen at 7 and 14 days&#xD;
      after their final prolactin injection. After a baseline prolactin level is drawn, milk will&#xD;
      be pumped until the breasts are emptied. Blood will be drawn at baseline and then every 10&#xD;
      minutes for 60 minutes, then every 30 minutes for a total of 3 hours to obtain a prolactin&#xD;
      peak.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Breast Milk Production</measure>
    <time_frame>28 days</time_frame>
    <description>Treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast Milk Prolactin Levels</measure>
    <time_frame>28 days</time_frame>
    <description>Treatment group</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Lactation</condition>
  <arm_group>
    <arm_group_label>recombinant human prolactin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label twice daily recombinant human prolactin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Prolactin</intervention_name>
    <arm_group_label>recombinant human prolactin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women, aged 18-45 years&#xD;
&#xD;
          -  Prolactin deficiency due to congenital deficiency, surgery or radiation, or Sheehan's&#xD;
             syndrome during the current or previous pregnancies, for women who desire to&#xD;
             breastfeed their infants.&#xD;
&#xD;
          -  Postpartum at the time of study participation&#xD;
&#xD;
          -  Milk must fail to come in by 2-4 days after delivery.&#xD;
&#xD;
          -  Prolactin levels will be less than the lower limit of normal for the assay performed.&#xD;
             If a subject is postpartum, prolactin levels will be less than the normal range for&#xD;
             postpartum women (&lt;= 138.0 Â± 11.9 ng/mL).&#xD;
&#xD;
          -  Free T4 index must be normal either on or off thyroid hormone replacement.&#xD;
&#xD;
          -  Fasting am cortisol or 1 hour Cortrosyn 0.25 mg stimulated cortisol must be normal&#xD;
             (&gt;18 mg/dL). If it is not normal, subjects must be on glucocorticoid replacement and&#xD;
             have no symptoms of adrenal insufficiency.&#xD;
&#xD;
          -  History of normal spontaneous puberty or Tanner stage V breast development after&#xD;
             previous estrogen replacement therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of medications known to increase or decrease prolactin&#xD;
&#xD;
          -  Anatomical breast abnormalities&#xD;
&#xD;
          -  Previous mammoplasty&#xD;
&#xD;
          -  Breast augmentation&#xD;
&#xD;
          -  Current use of hormonal contraception&#xD;
&#xD;
          -  Allergies to mannitol&#xD;
&#xD;
          -  Medications contraindicated for breastfeeding mothers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrine K Welt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 5, 2013</results_first_submitted>
  <results_first_submitted_qc>May 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2013</results_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Corrine Welt</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Lactation</keyword>
  <keyword>Breastfeeding</keyword>
  <keyword>Prolactin</keyword>
  <keyword>Primary lactation insufficiency</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2005-2008 Academic Hospital, clinical research center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Recombinant Human Prolactin Treatment</title>
          <description>Open label twice daily recombinant human prolactin 60 mcg/kg&#xD;
Recombinant Human Prolactin :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Recombinant Human Prolactin Treatment</title>
          <description>Open label twice daily recombinant human prolactin&#xD;
Recombinant Human Prolactin :</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Breast Milk Production</title>
        <description>Treatment group</description>
        <time_frame>28 days</time_frame>
        <population>One subject did not qualify after screening.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Prolactin Treatment</title>
            <description>Open label twice daily recombinant human prolactin&#xD;
Recombinant Human Prolactin :</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Milk Production</title>
          <description>Treatment group</description>
          <population>One subject did not qualify after screening.</population>
          <units>mL/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Milk Prolactin Levels</title>
        <description>Treatment group</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Prolactin Treatment</title>
            <description>Open label twice daily recombinant human prolactin 60 mcg/kg&#xD;
Recombinant Human Prolactin :</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Milk Prolactin Levels</title>
          <description>Treatment group</description>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Recombinant Human Prolactin Treatment</title>
          <description>Open label twice daily recombinant human prolactin&#xD;
Recombinant Human Prolactin :</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tingling in hands</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Red marks at injection site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers as this was an orphan disease trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Corrine Welt, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-716-8437</phone>
      <email>cwelt@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

